We are in absolutely agreement with authors about the improving effects of antiarrhythmic drug
therapy on prognosis in AF.
On occasion, apparently minor variations in gene sequences may combine with drugs, even certain antiarrhythmic drugs
As the man's condition showed no improvement, he was hospitalized at the medical center and was given a different antiarrhythmic drug
injection, the suit said.
The findings also reveal that the absence of efficacious antiarrhythmic agents with strong safety profiles is likely to continue as Gilead/Menarini's anti-anginal agent Ranexa (ranolazine) is the only antiarrhythmic drug
forecasted to launch through 2021.
Flecainide acetate is an antiarrhythmic drug
indicated for use in patients without structural heart disease for the prevention of paroxysmal supraventricular tachycardias (PSVT), including atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms as well as paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms.
The Cryo-FIRST (Catheter Cryoablation Versus Antiarrhythmic Drug
as First-Line Therapy of Paroxysmal Atrial Fibrillation) trial will evaluate the procedural success and clinical outcomes of patients with paroxysmal AF (PAF) undergoing cryoballoon ablation as an initial treatment compared with medication.
Heart rhythm experts generally prefer patients to have tried and failed at least one antiarrhythmic drug
, but that is not mandatory.
Therefore, reducing the frequency of symptomatic occurrences of atrial fibrillation is a key outcome of using antiarrhythmic drug
Another antiarrhythmic drug
, Brinavess, was filed in the US in 2007, but has still not received approval due to a patient suffering cardiogenic shock in a pivotal trial.
At 2-year follow-up, 72% of patients in the antiarrhythmic drug
group reached the primary efficacy outcome (time to first recurrence of symptomatic or asymptomatic AF /AT/AFL), compared with 55% in the ablation group, for a statistically significant risk reduction of 44%.
These differences persisted for the duration of the trial and were strongly associated with recurrent arrhythmias, which were much more frequent in the antiarrhythmic drug
The latest algorithm for antiarrhythmic drug
therapy to maintain sinus rhythm in patients with recurrent paroxysmal or persistent AF was recommended in 2001 by AHA/ACC/ESC guidelines (7).
The study found that, compared to treatment with antiarrhythmic drugs
, radiofrequency catheter ablation significantly extended the time to first recurrence of AFib, atrial tachyarrhythmia, atrial flutter and asymptomatic AFib, in patients with paroxysmal recurrent AFib who had not been previously treated with an antiarrhythmic drug
The CABANA (Catheter Ablation Versus Antiarrhythmic Drug
Therapy for Atrial Fibrillation) trial is a 3,000-patient, 5-year randomized study that recently began enrollment at a planned 180 centers worldwide.
The one year data from the Biosense Webster trial was recently published as the lead article in the January 27th issue of JAMA (Journal of the American Medical Association) where the study (A comparison of Antiarrhythmic Drug
Therapy and Radiofrequency Catheter Ablation in patients with Paroxysmal Atrial Fibrillation: A Randomized Controlled Trial by Wilbur et al) highlighted that patients with the most common heart rhythm disorder, Atrial Fibrillation, who were treated with catheter ablation using the NaviStar(R) ThermoCool(R) Catheter demonstrated significantly better outcomes at one year compared to those receiving antiarrhythmic drug